After an appeals court snubbed Pfizer’s proposed copay assistance programs for costly heart meds Vyndaqel and Vyndamax, the New York pharma turned to the Supreme Court. Now, as it awaits the justices’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results